Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy
Heart failure is one of the most common chronic medical conditions in the developed world. It is characterized by neurohormonal activation of multiple systems that can lead to clinical deterioration and significant morbidity and mortality. In this regard, hyponatremia is due to inappropriate and con...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.4061/2011/732746 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565182138679296 |
|---|---|
| author | Adam Romanovsky Sean Bagshaw Mitchell H. Rosner |
| author_facet | Adam Romanovsky Sean Bagshaw Mitchell H. Rosner |
| author_sort | Adam Romanovsky |
| collection | DOAJ |
| description | Heart failure is one of the most common chronic medical conditions in the developed world. It is characterized by neurohormonal activation of multiple systems that can lead to clinical deterioration and significant morbidity and mortality. In this regard, hyponatremia is due to inappropriate and continued vasopressin activity despite hypoosmolality and volume overload. Hyponatremia is also due to diuretic use in an attempt to manage volume overload. When hyponatremia occurs, it is a marker of heart failure severity and identifies patients with increased mortality. The recent introduction of specific vasopressin-receptor antagonists offers a targeted pharmacological approach to these pathophysiological derangements. Thus far, clinical trials with vasopressin-receptor antagonists have demonstrated an increase in free-water excretion, improvement in serum sodium, modest improvements in dyspnea but no improvement in mortality. Continued clinical trials with these agents are needed to determine their specific role in the treatment of both chronic and decompensated heart failure. |
| format | Article |
| id | doaj-art-9d2de6d14f434878bd324cc388f3f225 |
| institution | Kabale University |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-9d2de6d14f434878bd324cc388f3f2252025-02-03T01:09:02ZengWileyInternational Journal of Nephrology2090-214X2090-21582011-01-01201110.4061/2011/732746732746Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for TherapyAdam Romanovsky0Sean Bagshaw1Mitchell H. Rosner2Divsions of Nephrology and Critical Care, University of Alberta, Edmonton, AB, T6G 2G3, CanadaDivision of Critical Care, University of Alberta, Edmonton, AB, T6G 2G3, CanadaDivsion of Nephrology, University of Virginia Health System, Charlottesville, Box 800133, VA 22911, USAHeart failure is one of the most common chronic medical conditions in the developed world. It is characterized by neurohormonal activation of multiple systems that can lead to clinical deterioration and significant morbidity and mortality. In this regard, hyponatremia is due to inappropriate and continued vasopressin activity despite hypoosmolality and volume overload. Hyponatremia is also due to diuretic use in an attempt to manage volume overload. When hyponatremia occurs, it is a marker of heart failure severity and identifies patients with increased mortality. The recent introduction of specific vasopressin-receptor antagonists offers a targeted pharmacological approach to these pathophysiological derangements. Thus far, clinical trials with vasopressin-receptor antagonists have demonstrated an increase in free-water excretion, improvement in serum sodium, modest improvements in dyspnea but no improvement in mortality. Continued clinical trials with these agents are needed to determine their specific role in the treatment of both chronic and decompensated heart failure.http://dx.doi.org/10.4061/2011/732746 |
| spellingShingle | Adam Romanovsky Sean Bagshaw Mitchell H. Rosner Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy International Journal of Nephrology |
| title | Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy |
| title_full | Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy |
| title_fullStr | Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy |
| title_full_unstemmed | Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy |
| title_short | Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy |
| title_sort | hyponatremia and congestive heart failure a marker of increased mortality and a target for therapy |
| url | http://dx.doi.org/10.4061/2011/732746 |
| work_keys_str_mv | AT adamromanovsky hyponatremiaandcongestiveheartfailureamarkerofincreasedmortalityandatargetfortherapy AT seanbagshaw hyponatremiaandcongestiveheartfailureamarkerofincreasedmortalityandatargetfortherapy AT mitchellhrosner hyponatremiaandcongestiveheartfailureamarkerofincreasedmortalityandatargetfortherapy |